AbCellera Biologics Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
AbCellera Biologics Inc. (ABCL) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $10.43 million as of 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Notes › Goodwill and Other
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2022-05-10
- 2022-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $10.43M.
- 2021-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $10.30M.
- 2021-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $9.86M.
- 2021-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $9.86M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2022-03-31 | $10.43M 10-Q · filed 2022-05-10 |
| 2021-09-30 | $10.30M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $9.86M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $9.86M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |